National Center for Complementary and Integrative Health
To view a copy of this license, visit About this article Cite this article Zhang, J., An, H., Ni, K
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
Research Director National Institute of Integrative Medicine Copyright 2005-2026 Linus Pauling Institute Figure Alternative Text Figure 1
Recovery and reduced muscle damage: L-Carnitine has been shown to reduce markers of exercise-induced muscle damage, supporting faster recovery for active patients and athletes